# Flashpoint Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flashpoint-therapeutics

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.flashpoint.bio
- Total disclosed funding: $10M
- Latest round: Seed (Oct 25, 2023)
- Investors on record: 2

## About

Based in California, US, and founded in 2022, Flashpoint Therapeutics, Inc., operates as a biotechnology platform that develops nanotherapeutics used to deliver immune stimulatory molecules with nanoscale architecture and optimized activation kinetics. In October 2023, Flashpoint Therapeutics, Inc., raised USD 10 million in seed funding led by Beta Lab, with participation from CS Venture. As of 2023, the company is led by its CEO, Adam Margolin.

The company offers nanotechnology-enabled curative therapeutic solutions capable of delivering RNA, DNA, and peptide payloads to specific cells.

The company’s platform allows for combinations of therapeutic components and optimizes structure-function relationships and activation kinetics.

The company plans to use the October 2023 funding to increase the size of its team and improve its platform to create cutting-edge multi-targeted RNA, CRISPR, and peptide therapeutics.

## Funding rounds

- Seed, Oct 25, 2023, $10M — CS Venture, Beta Lab

## Investors

- CS Venture (https://capitalatlas.ai/funds/cs-venture) — Seed
- Beta Lab (https://capitalatlas.ai/funds/beta-lab) — Seed